Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion

被引:29
作者
Lambert, L. A. [1 ]
Whyteside, A. R. [1 ]
Turner, A. J. [1 ]
Usmani, B. A. [1 ]
机构
[1] Univ Leeds, Inst Mol & Cellular Biol, Fac Biol Sci, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England
关键词
endothelin-converting enzyme-1 (ECE-1); cell invasion; neprilysin; suppressor; prostate cancer;
D O I
10.1038/sj.bjc.6604631
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cross-talk between tumour and stromal cells can profoundly influence cancer cell invasion by increasing the availability of mitogenic peptides such as endothelin-1 (ET-1). Endothelin-1 is elevated in men with metastatic prostate cancer (PC), and can exert both an autocrine (epithelial) and a paracrine (stromal) influence on growth. Endothelin-1 is generated from its inactive precursor big-ET-1 by endothelin-converting enzyme 1 (ECE-1). We and others have demonstrated that ECE-1 expression is significantly elevated in tumours and surrounding stromal tissue. Our current data show siRNA-mediated knockdown of stromal ECE-1 reduces epithelial (PC-3) cell invasion in coculture. Interestingly, readdition of ET-1 only partially recovers this effect suggesting a novel role for ECE-1 independent of ET-1 activation. Parallel knockdown of ECE-1 in both stromal and epithelial compartments results in an additive decrease in cell invasion. We extrapolated this observation to the four recognised isoforms ECE-1a, ECE-1b, ECE-1c and ECE-1d. Only ECE-1a and ECE-1c were significant but with reciprocal effects on cell invasion. Transient ECE-1c overexpression increased PC-3 invasiveness through matrigel, whereas transient ECE-1a expression suppressed invasion. Furthermore, transient ECE-1a expression in stromal cells strongly counteracts the effect of transient ECE-1c expression in PC-3 cells. The ECE- 1 isoforms may, therefore, be relevant targets for antiinvasive therapy in prostate and other cancers.
引用
收藏
页码:1114 / 1120
页数:7
相关论文
共 31 条
[1]   Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium [J].
Ahmed, SI ;
Thompson, J ;
Coulson, JM ;
Woll, PJ .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2000, 22 (04) :422-431
[2]   The tumour microenvironment as a target for chemoprevention [J].
Albini, Adriana ;
Sporn, Michael B. .
NATURE REVIEWS CANCER, 2007, 7 (02) :139-147
[3]   Endothelin converting enzyme-1 expression in endometrial adenocarcinomas [J].
Arun, B ;
Kilic, G ;
Ashfaq, R ;
Saboorian, HM ;
Gokaslan, T .
CANCER INVESTIGATION, 2001, 19 (08) :779-782
[4]   Endothelin system in oral squamous carcinoma cells: Specific siRNA targeting of ECE-1 blocks cell proliferation [J].
Awano, S ;
Dawson, LA ;
Hunter, AR ;
Turner, AJ ;
Usmani, BA .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (07) :1645-1652
[5]   Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells [J].
Berger, Y ;
Delmilow, HI ;
Blum-Kaelin, D ;
Kitas, EA ;
Löffler, BM ;
Aebi, JD ;
Juillerat-Jeanneret, L .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (02) :483-498
[6]   Anti-peptide antibodies specific to rat endothelin-converting enzyme-1 isoforms reveal isoform localisation and expression [J].
Brown, CD ;
Barnes, K ;
Turner, AJ .
FEBS LETTERS, 1998, 424 (03) :183-187
[7]  
Dai J, 2001, CLIN CANCER RES, V7, P1370
[8]   Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression [J].
Dawson, LA ;
Maitland, NJ ;
Turner, AJ ;
Usmani, BA .
BRITISH JOURNAL OF CANCER, 2004, 90 (08) :1577-1582
[9]  
Dawson LA, 2006, EXP BIOL MED, V231, P1106
[10]  
Eberl LP, 2000, J CARDIOVASC PHARM, V36, pS354, DOI 10.1097/00005344-200036001-00103